Cited by 598Computational Drug Discovery MethodsPharmaceutical Economics and PolicyHistorical Medical Research and Treatments

The DOI matches its Crossref record; 85 of the 87 references it cites were found in a registry or an index.

Drug repurposing: a promising tool to accelerate the drug discovery process

Open access

Parvathaneni, Vineela, Kulkarni, Nishant S., Muth, Aaron, Gupta, Vivek·2019·Drug Discovery Today

DOI 10.1016/j.drudis.2019.06.014PMC PMC11920972

Open this paper in CoChat — free account

Abstract

Traditional drug discovery and development involves several stages for the discovery of a new drug and to obtain marketing approval. It is necessary to discover new strategies for reducing the drug discovery time frame. Today, drug repurposing has gained importance in identifying new therapeutic uses for already-available drugs. Typically, repurposing can be achieved serendipitously (unintentional fortunate observations) or through systematic approaches. Numerous strategies to discover new indications for FDA-approved drugs are discussed in this article. Drug repurposing has therefore become a productive approach for drug discovery because it provides a novel way to explore old drugs for new use but encounters several challenges. Some examples of different approaches are reviewed here.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.drudis.2019.06.014

Cites

85 of 85 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Drug repurposing: progress, challenges and recommendations
Pushpakom, S., Iorio, F., Eyers, P. A., Escott, K. J., Hopper, S., Wells, A., Doig, A., Guilliams, T., Latimer, J., McNamee, C., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.168 · Cited by 4,718
Drug repositioning: identifying and developing new uses for existing drugs
Ashburn, T. T., & Thor, K. B. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1468 · Cited by 3,237
New uses for old drugs
Chong, C. R., & Sullivan, D. J. (2007) · Nature · doi:10.1038/448645a · Cited by 996
Opportunities and challenges in phenotypic drug discovery: an industry perspective
Moffat, J. G., Vincent, F., Lee, J. A., Eder, J., & Prunotto, M. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.111 · Cited by 939
Rare cancers are not so rare: The rare cancer burden in Europe
Gatta, G., van der Zwan, J. M., Casali, P. G., Siesling, S., Tos, A. P. D., Kunkler, I. H., Otter, R., Licitra, L. F., Mallone, S., Tavilla, A., et al. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.08.008 · Cited by 813
Systematic integration of biomedical knowledge prioritizes drugs for repurposing
Himmelstein, D. S., Lizee, A., Hessler, C., Brueggeman, L., Chen, S. L., Hadley, D., Green, A., Khankhanian, P., & Baranzini, S. E. (2017) · eLife · doi:10.7554/elife.26726 · Cited by 666
Phase II failures: 2008–2010
Arrowsmith, J. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3439 · Cited by 622
Polypharmacology: drug discovery for the future
Reddy, A. S., & Zhang, S. (2012) · Expert Review of Clinical Pharmacology · doi:10.1586/ecp.12.74 · Cited by 498
Phase III and submission failures: 2007–2010
Arrowsmith, J. E. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3375 · Cited by 480
Phenotypic screens as a renewed approach for drug discovery
Zheng, W., Thorne, N., & McKew, J. C. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.07.001 · Cited by 438

Flagged first, then by citations

Show all 87 references

2 of the 87 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

Repurposing drugs helps patients with rare diseases. Available at: https://www.elsevier.com/connect/repurposing-drugs-helps-patients-with-rare-diseases.
Sekhon, 2013, Repositioning drugs and biologics: retargeting old/existing drugs for potential new therapeutic applications, J. Pharm. Educ. Res., 4, 1

Sorted by citations

Items 401–500 of 598

Repurposing antiplasmodial leads for cancer: Exploring the antiproliferative effects of N-cinnamoyl-aminoacridines
Fonte, M., Rôla, C., Santana, S., Prudêncio, M., Almeida, J., Ferraz, R., Prudêncio, C., Teixeira, C. A. S., & Gomes, P. A. C. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129894 · Cited by 1
Exploring Novel Therapeutic Avenues: Drug Repurposing for Neurodegenerative Movement Disorders
Bassi, P., Rana, S., Sapra, V., Raina, A., Kumar, P., & Devi, S. (2024) · Current Drug Research Reviews · doi:10.2174/0125899775327220240822111611 · Cited by 1
Biomarkers and Novel Therapies of Diabetic Neuropathy: An Updated Review
Aziz, N., Nehere, S. V., Sinha, R., Satyarthy, R., Prajapati, H., Panigrahy, U. P., Sharma, M. C., Kumar, P., & Wal, P. (2024) · Current Pharmaceutical Biotechnology · doi:10.2174/0113892010316518240924071259 · Cited by 1
A novel hypothesis‐generating computational workflow utilizing reverse pharmacophore mapping—A drug repurposing perspective of istradefylline towards major depressive disorder
der Walt, M. M. V., & Smith, A. P. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17346 · Cited by 1
“Traditional drug discovery takes approximately between 10 and 17 years from target identification to drug market availability (Parvathaneni et al., 2019), while DR takes approximately 3 to 12 years from compound identification to drug market availability (Hua et al., 2022).”
Repurposed pharmacotherapy: targeting cathepsin L with repurposed drugs in virtual screening
Khalid, M., Alqarni, M. H., & Foudah, A. I. (2024) · Molecular Diversity · doi:10.1007/s11030-024-11022-4 · Cited by 1
“This approach accelerates the discovery of new therapeutic applications and allows for a quicker translation of treatments to patients, particularly in addressing unmet medical needs [14].”
Drug Repositioning for Scorpion Envenomation Treatment Through Dual Inhibition of Chlorotoxin and Leiurotoxin
Gaouzi, Z., Abbou, H., Zegrari, R., Rachid, E. J., Diawara, I., Hakmi, M., & Mkamel, M. (2024) · Bioinformatics and Biology Insights · doi:10.1177/11779322241294130 · Cited by 1
“15 In this study, we will exploit drug-repositioning principles, through a pathogenic toxin-based neutralizing drug approach.”
Method
Extinguishing the flames of inflammation: retardant effect of chlorquinaldol on NLRP3-driven diseases
Wang, Z., Liu, J., Mou, Y., Li, Y., Liao, W., Yao, M., Wang, T., Shen, H., Sun, Q., & Tang, J. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01016-1 · Cited by 1
The assembled decoders to prepare for “bioactive X″ against progressive deterioration of liver disease: From NAFLD to HCC
Oh, K., Yoon, S. J., Eom, J. A., Lee, K. J., Kwon, G.-H., Kim, D. J., & Suk, K. T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117385 · Cited by 1
Identification of high-affinity inhibitors for epoxide hydrolase 2 from repurposed drugs in Parkinson’s disease therapeutics
Shamsi, A., Shahwan, M. J., Khan, S. N., Yadav, D. K., Altwaijry, N. A., Islam, A., & Khan, M. S. (2025) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2025.2497448 · Cited by 1
“Drug repurposing while combined with virtual screening approaches accelerates the drug development process, reduces costs, and expands treatment options to address unmet biomedical needs more efficiently (Parvathaneni et al., 2019).”
Discovery of Non-antibacterial Enrofloxacin Derivatives with Emerging Antiaging Effects through Drug Repurposing and Secondary Development
Qiao, S., Chen, X., Chen, Y., Song, Y., Shi, D., Mao, Z., Li, J., Huang, Y., & Liú, W. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00021 · Cited by 1
Targeting Mpox virus proteins with tea phytochemicals: A computational study
Arora, S., Kapgate, P., Girdekar, A., Moharir, K. S., Yende, S. R., Shah, S., & Harle, U. N. (2025) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2025.100337 · Cited by 1
Employing a drug repurposing strategy to identify B-cell lymphoma-2 (BCL-2) inhibitors with anticancer potential: An in silico and in vitro based study
Alaseem, A. M., Alasiri, G. A., Babu, M. A., Singh, T. G., Alam, P., Fareed, M., Akhter, M. S., & Bansal, N. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118364 · Cited by 1
Repurposing calcium channel blockers and cholinesterase inhibitors for antisnake venom therapy: a mechanistic literature review
Yusuf, A. J., Christian, T. T., Ibrahim, N., Alkali, Y. I., Aminu, J., Kamran, S., Barau, A. S., Hussain, N., Manshoor, N., & Salihu, M. (2025) · Discover Chemistry. · doi:10.1007/s44371-025-00272-2 · Cited by 1
Pharmacophore-Based Virtual Screening and Docking of Approved Drugs and Philippine Natural Products Targeting HIV-1 Protease
Costiniano, R., & Billones, J. B. (2025) · Journal Of Biochemical Technology · doi:10.51847/bq9kquzuzp · Cited by 1
Repositioning Triazoles as Phosphodiesterase‐4 Inhibitors to Suppress COVID ‐19 Cytokine Storms and Fungal Co‐Infections via Docking and Simulation
Almohaimeed, H. M., Chatterjee, A., Alaqabawi, M. R., Alsulaimani, F., Basri, A. M., Jafer, A., Shater, A. F., Saleh, F. M., Dhara, B., Uti, D. E., et al. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70902 · Cited by 1
In silico screening of potential FGF2 inhibitors for cancer therapy
Senrung, A. (2025) · In Silico Pharmacology · doi:10.1007/s40203-025-00495-2 · Cited by 1
“…such as molecular docking and molecular dynamic (MD) simulations to determine promising compounds by repurposing FDA-approved drugs could reduce cost and speed up the process of moving drugs to clinics (Filipe & Loura 2022; Paggi et al. 2024 ; Parvathaneni et al. 2019 ; Shaker et al. 2021).”
Evaluation of Polymyxin B as a Novel Vaccine Adjuvant and Its Immunological Comparison with FDA-Approved Adjuvants
Gulani, M. A., Harsoda, Y., Arte, T. M., D’Souza, M. J., Bagwe, P., Adediran, E. O., D’Souza, N., & Pasupuleti, D. (2025) · Vaccines · doi:10.3390/vaccines13121232 · Cited by 1
Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage
Shimoda, A., Murai, K., Hikita, H., Minami, S., Miyake, T., Kuriki, S., Sometani, E., Sung, J., Shigeno, S., Higuchi, Y., et al. (2026) · PLoS ONE · doi:10.1371/journal.pone.0340023 · Cited by 1
“In recent years, drug repurposing has emerged as a promising strategy to accelerate the identification of novel treatments [23].”
High-Throughput Screening of FDA-Approved Drugs for Antibacterial and Antibiofilm Activities Against Multidrug-resistant Pseudomonas aeruginosa
Guo, S., Li, H., Liu, B., Chen, C., Liu, H., & Zhang, Q. (2026) · ACS Omega · doi:10.1021/acsomega.5c12226 · Cited by 1
Systematic Examination of Gene Expression and Proteomic Evidence Across Tissues Supports the Role of Mitochondrial Dysregulation in ME/CFS
Keele, G. R., Enger, M., Barnette, Q., Ruiz-Esparza, R., Alvarado, M., Mathur, R., Stratford, J. K., Williams, S., Brown, L. M., Webb, B. T., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041997 · Cited by 1
“Bringing a novel drug to market is estimated to take over a decade and cost several billion dollars, making drug repurposing an appealing, cost-effective alternative [12–14].”
Large Library Docking for Polypharmacology
Wu, Y., Vigneron, S. F., Bráz, J. M., Srinivasan, K., Fink, E. A., Huang, X.-P., Xu, X., Huebner, H., Kim, J. Y., Wang, J., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c03810 · Cited by 1
Liposomal Amodiaquine for Localized Therapy of Non-Small Cell Lung Cancer (NSCLC)
Mokashi, M., Goyal, M., Rajana, N., & Gupta, V. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03369-8 · Cited by 1
“Drug repurposing presents an alternative approach to reduce the timeline for drug development, as well as providing a practical solution to address therapy resistance [13–16].”
Self-citation
DMAPLM: A multimodal pretrained framework for computational drug repositioning
Chen, H., & Li, Z. (2026) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1014192 · Cited by 1
Exploring drug repurposing for SGK1 inhibition: FDA-approved drugs and structural insights for new therapeutic strategies
Alrouji, M., AlOmeir, O., Alhajlah, S., Dinislam, K., Shahwan, M. J., & Shamsi, A. (2026) · Kuwait Journal of Science · doi:10.1016/j.kjs.2026.100606 · Cited by 1
Identification of Apixaban as a Potential Inhibitor of the SARS‐CoV‐2 Main Protease: A Multistage Computational Study
Metwaly, A. M., Alsfouk, B. A. A., Ibrahim, I. M., Elkaeed, E. B., & Eissa, I. H. (2026) · Journal of Chemistry · doi:10.1155/joch/3651186 · Cited by 1
Old drugs, new weapons: current trends in repurposing therapies against antimicrobial resistance
Gatadi, S., Kumar, N. P., Sridevi, B., Borra, P. B., Thapar, P., & Wani, A. (2026) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.3389/jpps.2026.16158 · Cited by 1
“High-throughput LC/MS, NMR, FIA-MS, and MALDI-FT-MS and related techniques assist in rapid filtration of hits with undesirable pharmacology and safety profiles and thereby support early ADME/toxicity prediction [149].”
Identifying potential inhibitors for wild-type EGFR tyrosine kinase through a cross-talk pathway strategy and an in-silico drug repurposing method
Abdelmalek, B. E., Bedchich, K., Smaoui, F., Kraiem, S., Mosrati, M. A., & Aifa, S. (2026) · PLoS ONE · doi:10.1371/journal.pone.0350847 · Cited by 1
“The overall picture was one of a ligand with both thermodynamic preference and kinetic stability a complementary and valuable combination in kinase inhibition [34–36].”
Advances in respiratory syncytial virus therapeutics: A comprehensive review of small-molecule inhibitors, monoclonal antibodies, and vaccines
Bai, G., Huang, X., & He, Y. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.119092 · Cited by 1
GLP-1 receptor agonists in dermatology: Prescribing frameworks, access, and the emerging pipeline
Bridges, A. G. (2026) · Clinics in Dermatology · doi:10.1016/j.clindermatol.2026.09.018 · Cited by 1
Drug Repurposing and Dosage Form Development of Anti-COVID-19
Kwok, K. (2021) · Pharmaceutical Sciences and Research · doi:10.7454/psr.v8i1.1200 · Cited by 1
“In addition, drug repurposing can also reduce the costs required in its process and has lesser risk in the research (Agrawal, 2015; Parvathaneni et al., 2019; Zhou et al., 2020).”
Background
Global Drug Repurposing Research from 2000 to 2018: A Bibliometric Analysis
Li, W., & Wan, L. (2021) · Advances in Bioscience and Bioengineering · doi:10.11648/j.abb.20210902.14 · Cited by 1
Statins as an antiepileptogenic or disease-modifying treatment? A survey of what UK patients and significant others think about repurposing and trialing them for epilepsy
Noble, A. J., Dixon, P., Roper, L., Marson, A. G., & Mirza, N. (2022) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2022.108991 · Cited by 1
“Existing safety data might, for instance, permit the phase-1 trial stage to be bypassed [9].”
Background
Drug Repurposing for COVID-19 Therapy: Pipeline, Current Status and Challenges
Verma, R., Raj, S., Berry, U., Ranjith-Kumar, C. T., & Surjit, M. (2023) · Springer eBooks · doi:10.1007/978-981-19-5399-6_19 · Cited by 1
Strategies to Combat Multidrug Resistance by Non-traditional Therapeutic Approaches
Yadav, H., Maurya, A., Agarwal, A., Singh, A. K., Dubey, S., Tamang, A. M., Agrawal, R., & Chaudhary, S. K. (2023) · Springer eBooks · doi:10.1007/978-981-19-9167-7_3 · Cited by 1
Pharmacophore Modeling Guided by Conformational Dynamics Reveals Potent Anticancer Agents
Kantarci-Carsibasi, N. (2023) · Süleyman Demirel Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.19113/sdufenbed.1121167 · Cited by 1
Old drugs and new opportunities—Drug repurposing in colon cancer prevention
Sarojamma, V., Gupta, M. K., Shaik, J. B., & Vadde, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15280-1.00010-8 · Cited by 1
CHALLENGES AND OPPORTUNITIES WITH DRUG REPURPOSING: AN EMERGING TECHNIQUE IN DRUGS DISCOVERY
Harale, S., Hupare, P., Ghatage, P., Govande, V., Gurav, O., Bandgar, S. A., Patil, S. P., & Gaikwad, D. (2023) · INDIAN DRUGS · doi:10.53879/id.60.11.13058 · Cited by 1
Insights into the eradication of drug resistant Staphylococcus aureus via compound 6-nitrobenzo[ cd ]indole-2(1 H )-ketone
Qin, H., Li, L., Chen, S., Han, X., Min, R., Guo, Y., Liu, T., & Zhao, C. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb02686h · Cited by 1
A Review on Repurposing of Drug
Jannat, A., Rafique, S., Javed, S., Habib, A., & Afzal, Z. (2024) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs0202317112 · Cited by 1
Forensic Drug Chemistry: Unravelling Evidence Through Scientific Analysis
Ikbal, A. M. A., Debnath, R., Thomas, S., Chattopadhyay, D., & Palit, P. (2024) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-97-1148-2_16 · Cited by 2
Computational Drug Design Strategies for Fighting the COVID-19 Pandemic
Hakmi, M., Bouricha, E. M., Soussi, A., Bzioui, I. A., Belyamani, L., & Ibrahimi, A. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-61939-7_11 · Cited by 1
Hub Gene Clusters Reveal Dysregulated Synaptic Neurotransmitter Signaling Pathways and Drug Repurposing Prospect in Brain Tumors
Villanueva, B. H. A., Tsai, P., & Tayo, L. L. (2026) · Onco · doi:10.3390/onco6020022 · Cited by 2
“Therefore, drug repurposing is a promising approach in drug search, providing readily available drug options for brain tumors [16].”
Analyzing Thermal Degradation of Furvina Drug Using a Stability Indicating Spectrophotometric Method and Characterization Studies
Valdés-Negrín, H. L., Álvarez, O., Pérez-Rodríguez, Z., Negrín, Z. R., & Pérez-Rodríguez, M. (2022) · Chemistry Africa · doi:10.1007/s42250-021-00307-y · Cited by 1
Repurposing Molnupiravir as a new opportunity to treat COVID-19
Sahithi, P., Yetukuri, K., & Nadendla, R. (2022) · Journal of Generic Medicines The Business Journal for the Generic Medicines Sector · doi:10.1177/17411343221115819 · Cited by 1
“Because data about safety, effectiveness, and the proper delivery route is available, less efforts are necessary to bring a repositioned medicine to commercialization.(10) The most challenging component of product repositioning is discovering novel drug responses.”
Background
COVID-19 Drug Development: Role of Drug Repurposing
David, K. B., Azeez, Y. O., & Okafor, C. C. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.107939 · Cited by 1
Editorial: Repurposed Drugs Targeting Cancer Signaling Pathways: Dissecting New Mechanism of Action Through In Vitro and In Vivo Analyses
López–Urrutia, E., Padilla‐Benavides, T., Pérez‐Plasencia, C., & Campos-Parra, A. D. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.773429 · Cited by 1
Identification and Development of Therapeutics for COVID-19.Preprint
Rando, H. M., Wellhausen, N., Ghosh, S., Lee, A. J., Dattoli, A. A., Hu, F., Byrd, J. B., Rafizadeh, D. N., Lordan, R., Qi, Y., et al. (2021) · PubMed · Cited by 1
Drug Repurposing in Alternative Medicine: Sochehwan, a Polyherbal Traditional Korean Digestant, Protects against Alcoholic Steatohepatitis by Regulating Cytochrome P450 2E1 Expression
Yu, G., Lee, S., Lim, D., Kim, H., Kim, J., & Park, W. (2021) · Processes · doi:10.3390/pr9101760
“Based on the well-studied pharmacokinetic profiles and safety data from clinical trials, it provides an innovative means of discovering new indications for existing drugs, which can save cost, time, and resources [16,17].”
Background
Viral Drug prediction with Matrix Decomposition and Two-layer Heterogeneous Graph InferencePreprint
Qu, J., Cheng, X.-L., Bian, Z., Ni, T., & Guan, N.-N. (2021) · Research Square · doi:10.21203/rs.3.rs-1063392/v1
Repurposing Approved Drugs to Block Highly Pathogenic Emerging Viruses
Mercorelli, B., & Loregian, A. (2021) · Royal Society of Chemistry eBooks · doi:10.1039/9781788016858-00232
Project SCANCER: An Open-access Drug Repurposing and Data-mining Platform to Enhance Target Validation and Optimize International Research Efforts against Highly Progressive CancersPreprint
Dóra, D., Dóra, T. B., Szegvári, G., Gerdán, C., & Lohinai, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1257157/v1
“Nowadays, a wide selection of databases is available for various goals in drug repurposing (Parvathaneni et al., 2019; Gns et al., 2019; Tanoli et al., 2021).”
Background
Role of Academia: Drug Repurposing to Induce Autophagy for Treatment of Neurodegenerative Diseases
Fernandez-Estévez, M., Wróbel, L., & Rubinsztein, D. C. (2022) · Royal Society of Chemistry eBooks · doi:10.1039/9781839163401-00014
Screening of a FDA-Approved Compound Library Identifies Menadione in Regulating Colon Cancer Programmed Death via MAPK8 CascadesPreprint
Song, W., Cao, L., Ding, L., Ma, X., Gu, P., Wang, W., Sun, J., & Mu, W. (2022) · Research Square · doi:10.21203/rs.3.rs-1406834/v1
Topology-Enhanced Molecular Graph Representation for Anti-Breast Cancer Drug Selection (Preprint)Preprint
Gao, Y., Chen, S., Tong, J., Yan, C., & Fu, X. (2022) · doi:10.2196/preprints.37601
AI based strategies for Covid-19 drug repurposing.Preprint
Srivastava, S., Preeti, P., Sharma, T., Goel, S., Rajput, K. G., & Rawal, K. (2022) · doi:10.31219/osf.io/c2u4x
Búsqueda de nuevos fármacos antichagásicos inhibidores de la Tripanotión sintetasa
Alice, J. I. (2022) · doi:10.35537/10915/137336
Discovery of inhibitors of the SARS-CoV-2 S-protein through drug computational drug repurposingPreprint
Rubio, J., Montejo, M., Pérez, J. J., & Granadino‐Roldán, J. M. (2022) · ChemRxiv · doi:10.26434/chemrxiv-2022-n2zmh
DeepsmirUD: Precise prediction of regulatory effects on miRNA expression mediated by small molecular compounds using competing deep learning frameworksPreprint
Sun, J., Ru, J., Chen, Z., Qi, F., Ramos‐Mucci, L., Chen, S., Cribbs, A. P., Deng, L., & Wang, X. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.30.498304
“By utilizing miRNA-cancer associations from miRCancer and SM-miR relations predicted by DeepsmirUD, we generated SM–disease relationships for drug discovery and repositioning [61–63] to demonstrate the ability of SMs to affect miRNA perturbation profiles in cancers.”
Method
Charted Territory: Evidence from Mapping the Cancer Genome and R&D Decisions in the Pharmaceutical IndustryPreprint
Kao, J. (2021) · Social Science Research Network · doi:10.2139/ssrn.3883041 · Cited by 5
Screening strategies for drug discovery-focus on ocular hypertension
Sharif, N. A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-819291-7.00039-3
Mendelian Randomization Identified CHRNE as a Potential Drug Target for Alzheimer’s diseasePreprint
Li, M.-L., Yang, Y., Song, B., Yang, J., Fan, L., & Xu, Y. (2022) · Research Square · doi:10.21203/rs.3.rs-1940818/v1
DEDTI vs IEDTI: Efficient and Predictive Models of Drug-Target InteractionsPreprint
Zabihian, A., Sayyad, F. Z., Hashemi, S. M., Hooshmand, M., & Gharaghani, S. (2022) · Research Square · doi:10.21203/rs.3.rs-2070026/v1
REPOSICIONAMENTO DE FÁRMACOS GUIADO POR MODELO DE INTELIGÊNCIA ARTIFICIAL NA OSTEOPOROSE
Silva, A. D. D., Sousa, G. A., Alves, V. S., Santos, A. J. P. A. D., Brayner, J. G. M., & Braz, H. L. B. (2022) · Brazilian Journal of Case Reports · doi:10.52600/2763-583x.bjcr.2022.2.suppl.3.249-254
Regulatory perspective of Drug Repurposing: Methods, Regulatory pathways and Hurdles
Verma, S., Vaghela, K., & Zaveri, M. (2022) · International Journal of Drug Regulatory Affairs · doi:10.22270/ijdra.v10i2.520
DRUG REPURPOSING OF COMMERCIALLY AVAILABLE AZOLES AGAINST ASPERGILLOSIS PEROXIREDOXIN ASP F3 ALLERGEN DRUGS
SREERAJ, S., & Pranav, K. V. A. (2023) · Innovare Journal of Medical Sciences · doi:10.22159/ijms.2023.v11i2.47142
Repurposing Drugs: A New Paradigm and Hopes for Life-threatening Diseases
Chawla, R., Rani, V., Kumar, K., & Mishra, M. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123197123010004
High Throughput Screening (HTS) Methods for Screening of Known Drugs for COVID-19
Shreeya, T., & Qidwai, T. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815123197123010009
Facilitating the drug repurposing with iC/E strategy: A practice on novel nNOS inhibitor discovery
Hu, Z., Liu, Q., & Zhong, N. (2023) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s021972002350018x
Computational repurposing of Trimethoprim: molecular docking and molecular dynamics simulation studies suggest a potential inhibition of colchicine-binding site.Preprint
Osama, S., Shahin, M. I., Elrazaz, E. Z., & Abouzid, K. A. M. (2023) · Research Square · doi:10.21203/rs.3.rs-3515239/v1
A panorama to mine “bioactive X” against progressive deterioration of liver disease: from NAFLD to HCCPreprint
Oh, K., Yoon, S. J., Eom, J. A., Lee, K. J., Kwon, G.-H., Kim, D. J., & Suk, K. T. (2023) · Research Square · doi:10.21203/rs.3.rs-3565330/v1
THE LATEST IDEAS OF MEDICAL AND BIOLOGICAL DEVELOPMENTS AND IMPROVEMENT OF PSYCHOLOGICAL SCIENCES BY SCIENTISTS
Vladlenov, D., Bereziuk, O. V., Vasenko, T. B., Нrynchak, N., Sprut, O., Kurdil, N. V., Бортний, М., Бірюков, В., Ковтун, Л., Savychuk, O., et al. (2023) · Іnternational Science Group eBooks · doi:10.46299/isg.2023.mono.med.4
Therapeutic outcomes arising from adverse drug reactions
Heerfordt, I. M., Rix, I., & Horwitz, H. (2023) · Adverse Drug Reaction Bulletin · doi:10.1097/fad.0000000000000071
“1,2 In article, we examine a speci c type drug repurposing, which involves utilizing unintended adverse reactions of drug as novel therapeutic indication We review ﬁ ve distinct examples shed light on the interplay between unintended implications and the potential innovative treatments.”
Background
Computational Molecular Docking Studies of Small Molecule Inhibitors With the SARS-CoV-2 Spike Protein Variants: In-Silico Drug Discovery Using Virtual Screening and Drug Repurposing Approaches
Gupta, G. (2023) · doi:10.36837/chapman.000515
Reposicionamento de antirreabsortivos para tratamento da sobrecarga de ferro
Konno, J. T. L. (2023) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.46.2023.tde-11122023-142506
Unlocking New Potential: Drug Repurposing and Innovative Pharmaceutics
Lunawat, A. K., & Raikwar, S. (2024) · Current Drug Research Reviews · doi:10.2174/0125899775282901240130113010
Novel strategies for drug repurposing
Takundwa, M. M., & Raj, D. B. T. G. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.03.021
Compound Screening and Prioritization in Drug Discovery Using Machine Learning
Mariyam, A. A., Varshni, R. R., Samyuktha, S. P., Kumar, V. A., & Narmadha, B. (2024) · IEEE International Students' Conference on Electrical, Electronics and Computer Science (SCEECS) · doi:10.1109/sceecs61402.2024.10481962
AI-Driven Drug Repurposing for COVID-19: Revolutionizing Therapeutic Discovery and Treatment StrategiesPreprint
Rustagi, A., Chopra, A., Aggarwal, S., Gautam, Y., Ramesh, B., Tanwar, S., Anand, A., & Rawal, K. (2024) · doi:10.31219/osf.io/69rek
Discovery of SARS-CoV-2 Antiviral Drugs Through Large-Scale Virtual Screening of FDA-Approved Drugs
Ezzemani, W., Ouladlahsen, A., Altawalah, H., Saı̈le, R., Sarih, M., Kettani, A., & Ezzikouri, S. (2024) · Livestock diseases and management · doi:10.1007/978-981-99-9195-2_12
Identification and characterization of malaria box compounds possessing inhibition effect on the SARS-CoV2 spike protein
Sangvansindhu, C. (2024) · Chulalongkorn Medical Journal · doi:10.56808/2673-060x.5424
In silico comparative analysis of cestode and human NPC1 provides insights for ezetimibe repurposing to visceral cestodiases treatment
Corá, R. K., Paludo, G. P., Paes, J. A., & Ferreira, H. B. (2024) · Scientific Reports · doi:10.1038/s41598-024-72136-1
“This approach bypasses stages of the research process, exploring innovative ways of repurposing existing drugs that have already been approved for use or are in advanced pre-clinical stages 13 .”
In silico-driven identification of Pranlukast as a Stabilizer of PD-L1 Homodimers
Córdova-Bahena, L., Landero-Marín, C., Flores-Hernández, X., Alvarez-Coronel, L. D., Jiménez‐Uribe, A. P., Salinas-Jazmín, N., An, Z., & Velasco-Velázquez, M. A. (2024) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/0118715206303675241009104647
Antiedematogenic and Anti‐Inflammatory Effects of the Essential Oil from the Fruits of Piper tuberculatum Jacq. (Piperaceae) in Animal Models
da Silva, L. Y. S., Pessoa, R. T., Alcântara, I. S., Silva, E. D. S., da Silva, A. B., Junior, S. C. A., Saraiva, R. D. A., Oliveira‐Tintino, C. D. D. M., Ribeiro‐Filho, J., & de Menezes, I. R. A. (2024) · Chemistry & Biodiversity · doi:10.1002/cbdv.202402219
A gyógyszer-repozicionálás és klinikai diabetológiai vonatkozásai
Pokoly, B., & Somogyi, A. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33177
The Recurrent Neural Networks: Algorithm Driven Alchemy of Machine Learning into Precision Therapeutics for Today and TomorrowPreprint
Srivastava, H., Leel, M., Singh, P., Rashmi, R., Kumar, A., & Kumar, S. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5091386
Transforming Alzheimer's Treatment: Unveiling New Potential with Drug Repurposing Strategies
Mishra, A. S., Vasanthan, M. V. M., Ghosh, B., & Sivakumar, P. M. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673341391241231054936
Drug Repurposing Through Molecular Docking
Tripathi, R. K. P. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-5598-5.ch009
Multi-omics and drug development
Hamid, S., Bhat, A. A., Bhat, M. R., Assad, A., & Macha, M. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13595-8.00007-6
Introductory Chapter: Repurposed Drugs – Current State and Future Perspectives
Engin, S. (2025) · Pharmaceutical science. · doi:10.5772/intechopen.1008838
Wrangling Real-World Data: Optimizing Clinical Research Through Factor Selection with LASSO Regression
Howard, K. A., Anderson, W., Podichetty, J. T., Gould, R., Boyce, D. M., Dasher, P., Evans, L., Kao, C., Kumar, V. K., Hamilton, C., et al. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22040464
“Drug repurposing may be less expensive, less time-consuming, and safer, as approved drugs have already gone through extensive safety testing, and many preclinical and early phase clinical trials may not be necessary [7,8,13].”
In vitro enzymatic and cell culture assays for SARS-CoV-2 main protease interaction with ambenonium
de Souza, J. Â., Gomes, I. D. S., Fernandes, L. D. S., Andrade, L. A. F., de Souza, L. Â., Paiva, V. D. A., Araújo, S. C., de Lima, L. H. F., Dias, R. S., de Melo-Minardi, R. C., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-94283-9
Repositioning Fluoxetine as a TRPV3 Channel Inhibitor to Alleviate Skin Inflammation and Pruritus
Zhang, L., Chang, J., Xu, Y., Ge, Q., & Zhang, C. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040277
“Unlike traditional drug discovery, drug repurposing has emerged as a promising means for expediting the drug discovery process [23].”
Application of Bioinformatics in Receptor Biology and Drug Discovery
Panwar, V., Lalhlenmawia, H., Bisht, D., Arya, R. K. K., & Kumar, D. (2025) · The Receptors · doi:10.1007/978-3-031-81991-9_20
Unveiling sub-populations in critical care settings: a real-world data approach in COVID-19
Anderson, W., Gould, R., Patil, N., Mohr, N. M., Dodd, K. W., Boyce, D. M., Dasher, P., Guerin, P. J., Khan, R., Cheruku, S., et al. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1544904 · Cited by 1
Modern Computational Intelligence Based Drug Repurposing for Cancer
Budha, R. R., Khan, N., Khan, S., Attar, E. S., & Rao, G. K. (2025) · Springer eBooks · doi:10.1007/978-981-96-4154-3_23
Deciphering Therapeutic Targeting of Cathepsin B Using Repurposed Drug Darifenacin
Mukhopadhyay, S., Kandasamy, T., Iyer, P. K., & Ghosh, S. S. (2025) · ChemMedChem · doi:10.1002/cmdc.202500117
An accessible, timely method for identifying medications for repurposing: hypothesis generating; testing and validation
Lange, M., Gogarty, E., Martyn, M., Braude, P., Fayez, F., Koutsouleris, N., Howes, O. D., Twumasi, R., & Carter, B. (2025) · BMC Digital Health · doi:10.1186/s44247-025-00170-8
“Artificial intelligence has shown promise in drug repositioning and repurposing, helping to identify new indications for existing drugs more efficiently and cost-effective (for reviews see [8, 10–17].”
Exploring Alectinib and Irinotecan as potential human kallikrein-1 inhibitors: a drug repurposing approach for cancer and dermatological disorders
Jawaid, T., Kamal, M., Al‐Keridis, L. A., Adnan, M., Hussain, I., Alshammari, S. O., Alshammari, N. I., Azum, N., & Mohammad, T. (2025) · Molecular Simulation · doi:10.1080/08927022.2025.2507769
“Drug repurposing, identifying new therapeutic indications for approved (or investigational) drugs, has become an important strategy [3].”
Treatment of Neurodevelopmental Disorders
van Karnebeek, C., Berry‐Kravis, E., & Gropman, A. L. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-10944-7.00079-2
Insilico investigation of novel Plasmodium Falciparum Glycogen Synthase Kinase( pf GSk3β) inhibitors for the treatment of malaria infectionPreprint
Adebambo, K. F., & Ottify, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.06.07.658456
“According”

Authors: Parvathaneni, V., Kulkarni, N. S., Muth, A., & Gupta, V.
Affiliations: St. John's University (US)
Corresponding author: Gupta, Vivek
ORCID: Parvathaneni, Vineela
Muth, Aaron
Gupta, Vivek
Venue: Drug Discovery Today
Publisher: Elsevier BV
Published: 2019-10
Volume: 24
Issue: 10
Pages: 2076-2085
ISSN: 1359-6446 (ISSN-L)
DOI: 10.1016/j.drudis.2019.06.014
PMC: PMC11920972
OpenAlex: W2951512731
Semantic Scholar: 023e169dfa4fe591ef24cf91b93e0d7371bb3400
Cited by: 597
References: 87
Citations by year: 2026: 80 · 2025: 137 · 2024: 130 · 2023: 96 · 2022: 77 · 2021: 52 · 2020: 22 · 2019: 3
FWCI: 3.18
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: Drug Discovery Today (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Figshare (submittedVersion, cc-by)
Health Research Alliance (cc-by)
Funders: NIH (1R15HL138606-01A1)
American Heart Association (18AIREA33960072)
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
Keywords: drug repurposing, FDA-approved drugs, new therapeutic indications, serendipitous drug discovery, drug development challenges
MeSH terms: Humans, Drug Discovery, Drug Repositioning

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Drug repurposing: a promising tool to accelerate the drug discovery process

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks